Praxis Precision Medicines, Inc. will be at the International Epilepsy Congress in Lisbon, Portugal from August 30 to September 3, 2025. The company will present data from the RADIANT study in focal onset seizures, along with updates on their precision epilepsy pipeline. They will also share results from studies on Vormatrigine, Relutrigine, and Elsunersen, highlighting their potential to transform the epilepsy treatment landscape. Praxis aims to engage with the clinical and advocacy communities, emphasizing their patient-centered approach to developing treatments. Attendees can explore their work at Booth #435 and scientific exhibit, and participate in various scientific presentations throughout the event.

Read more at GlobeNewswire: Praxis Medicines to Present at 36th International Epilepsy